Robust vision gains¹

• Gains achieved with a majority of patients on q12w²

Mean change in VA of Beovu^® vs aflibercept^2,3

• The vision gains were maintained at Week 96^2*

q12w=treatment every 12 weeks
The primary efficacy endpoint for the studies was the change from baseline in BCVA at Week 48 as measured by the ETDRS Letter Score with the primary objective to demonstrate noninferiority of Beovu vs aflibercept. Beovu (q12w/q8w) demonstrated noninferiority in VA to aflibercept 2 mg (fixed q8w).
*No hypothesis testing was performed after Week 48.

REFERENCES

1. Dugel PU, Koh A, Ogura Y, et al; on behalf of the HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72-123.

2. Summary of Product Characteristics. Novartis; 2020.

3. Data on file. BCVA Data. Novartis; 2019.

Beovu^® SmPC